Group leader: Andrew Urquhart
Ocular Drug Delivery
The ocular drug delivery (ODD) group's research mission is to develop novel nanotherapeutic strategies for the treatment of degenerative diseases of the retina that lead to irreversible vision loss and blindness (e.g. diabetic retinopathy, glaucoma and age-related macular degeneration). Our strategy to achieve this mission is to understand the fundamental properties that enhance the efficacies of nanotherapeutics in the eye and implement this understanding in the development of better nanotherapeutics. Our research is driven by the need to provide new therapies to degenerative retinal diseases that remain highly challenging to treat in the clinic and have a significant impact on patient quality of life. The ODD group work at the interface between biology, materials and nanotechnology.